{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=45&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Tampa",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 9128,
    "total_pages": 913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=46&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=44&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T21:05:12.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03978520",
      "title": "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "Elsubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for elsubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 341,
      "start_date": "2019-07-25",
      "completion_date": "2022-07-14",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 47,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978520"
    },
    {
      "nct_id": "NCT04538482",
      "title": "DASH INtervention to INvestigate the Gut",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Microbiota",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "DASH Diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "standard American diet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 115,
      "start_date": "2022-03-07",
      "completion_date": "2026-03-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04538482"
    },
    {
      "nct_id": "NCT01252355",
      "title": "Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis Relapse"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-beta (IFN-beta)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 534,
      "start_date": "2011-01",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 32,
      "location_summary": "Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Cordova",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01252355"
    },
    {
      "nct_id": "NCT05145491",
      "title": "Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epiretinal Membrane"
      ],
      "interventions": [
        {
          "name": "Immediate Vitrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Deferred Vitrectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2022-02-22",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Glendale, California • Huntington Beach, California + 41 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145491"
    },
    {
      "nct_id": "NCT01508338",
      "title": "The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Experienced Weight Training Males"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "HMB",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Peak ATP and HMB",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "ATP",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Metabolic Technologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "18 Years to 30 Years · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2012-01",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01508338"
    },
    {
      "nct_id": "NCT02907385",
      "title": "Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rectal Cancer",
        "Anastomotic Leak"
      ],
      "interventions": [
        {
          "name": "LifeSeal™ Kit",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "LifeBond Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 736,
      "start_date": "2016-11",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Stanford, California • Florida City, Florida + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Florida City",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02907385"
    },
    {
      "nct_id": "NCT03177291",
      "title": "Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Advanced Cancer",
        "Metastatic Lung Cancer",
        "Squamous Cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2017-09-26",
      "completion_date": "2024-12-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03177291"
    },
    {
      "nct_id": "NCT07213674",
      "title": "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Xaluritamig",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 750,
      "start_date": "2025-11-28",
      "completion_date": "2032-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 46,
      "location_summary": "Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07213674"
    },
    {
      "nct_id": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non-small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Carcinoma",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM831",
          "type": "DRUG"
        },
        {
          "name": "NGM831 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-31",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05215574"
    },
    {
      "nct_id": "NCT02325791",
      "title": "Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "Suptavumab 30 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matched to Suptavumab",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg- 1 Dose",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg - 2 Doses",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 1177,
      "start_date": "2015-07-21",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-11-05T21:05:12.315Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325791"
    }
  ]
}